These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36298558)

  • 1. Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients.
    Bhadauria DS; Katiyar H; Goel A; Tiwari P; Kishore RVK; Aggarwal A; Verma A; Khetan D; Kaul A; Yachha M; Behera MR; Yadav B; Prasad N
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to ChAdOx1 nCoV-19 (Covishield®) vaccine in people on maintenance hemodialysis.
    Bhadauria DS; Tiwari P; Goel A; Katiyar H; Kaul A; Mayank ; Aggarwal A; Verma A; Khetan D; Yachha M; Behera MR; Yadav B; Agarwal K; Prasad N
    Semin Dial; 2023; 36(6):477-482. PubMed ID: 36843062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield
    Goel A; Verma A; Tiwari P; Katiyar H; Aggarwal A; Khetan D; Mayank ; Kishore RVK; Kumar P; Singh TP; Sheikh S; Vaishnav M; Pathak P; Shalimar
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of ChAdOx1 nCoV-19 (Covishield
    Verma A; Goel A; Katiyar H; Tiwari P; Mayank ; Sana A; Khetan D; Bhadauria DS; Raja A; Khokher N; Shalimar ; Singh RK; Aggarwal A
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform.
    Patil R; Palkar S; Mishra A; Patil R; Arankalle V
    Front Immunol; 2023; 14():1181991. PubMed ID: 37342350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-vaccination analysis of anti-spike antibody responses in kidney transplant recipients with and without COVID-19 infection in a tertiary care centre, India.
    Jasuja S; Jha V; Sagar G; Bahl A; Verma S; Jasuja N; Kaur J
    Clin Kidney J; 2022 Jul; 15(7):1312-1321. PubMed ID: 35747093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers.
    Watcharananan SP; Jaru-Ampornpan P; Sahawongcharoen S; Naitook N; Himananto O; Jongkaewwattana A; Setthaudom C; Rattanasiri S; Phuphuakrat A; Thakkinstian A; Mavichak V;
    Am J Transplant; 2022 May; 22(5):1459-1466. PubMed ID: 35090091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients.
    Ohki Y; Kawabe M; Yamamoto I; Katsumata H; Nakada Y; Kobayashi A; Urabe F; Miki J; Yamada H; Kimura T; Matsuo N; Tanno Y; Horino T; Ohkido I; Yamamoto H; Yokoo T
    Front Microbiol; 2022; 13():922042. PubMed ID: 35756063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Manomaipiboon A; Phumisantiphong U; Maneerit J; Chalearmchai Y; Jirawathin W; Prajongsai A; Phankavong P; Trakarnvanich T
    Vaccine; 2022 Jan; 40(4):587-593. PubMed ID: 34969542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
    Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
    Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.